{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:49:58Z","timestamp":1792180198155,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2026.201158","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:05:04Z","timestamp":1771434304000},"page":"201158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antigen-binding affinity is a key determinant of the durable antitumor activity of CD5 CAR-T cells"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-5687","authenticated-orcid":false,"given":"Jeong-Hoon","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Ri","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Rok","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Bhin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong Ji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Jeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1660-854X","authenticated-orcid":false,"given":"Young-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201158_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.967754","article-title":"Chimeric antigen receptor T-cell therapy for T-ALL and AML","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201158_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12943-023-01904-w","article-title":"Therapeutic challenges in peripheral T-cell lymphoma","volume":"23","author":"Luan","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201158_bib3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2019.03.004","article-title":"Mogamulizumab for the Treatment of Adult T-cell Leukemia\/Lymphoma","volume":"19","author":"Ureshino","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.omton.2026.201158_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3324\/haematol.2023.283740","article-title":"Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant","volume":"109","author":"Begna","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201158_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.omton.2026.201158_bib6","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201158_bib7","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201158_bib8","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201158_bib9","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201158_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/vaccines11010165","article-title":"CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities","volume":"11","author":"Ren","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.omton.2026.201158_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?","volume":"9","author":"Maciocia","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201158_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201158_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1268","article-title":"Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma","volume":"10","author":"Alvarez-Fern\u00e1ndez","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.omton.2026.201158_bib14","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201158_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201158_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201158_bib17","article-title":"Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity","volume":"5","author":"Ma","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omton.2026.201158_bib18","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","article-title":"Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells","volume":"186","author":"Tsuchida","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201158_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-024-00561-1","article-title":"CRISPR-Cas9 applications in T cells and adoptive T cell therapies","volume":"29","author":"Chen","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.omton.2026.201158_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41551-024-01277-5","article-title":"Large DNA deletions occur during DNA repair at 20-fold lower frequency for base editors and prime editors than for Cas9 nucleases","volume":"9","author":"Hwang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omton.2026.201158_bib21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201158_bib22","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201158_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201158_bib24","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201158_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032403","article-title":"The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better","volume":"13","author":"Mao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201158_bib26","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/jcm11082158","article-title":"Development of CAR T Cell Therapy in Children-A Comprehensive Overview","volume":"11","author":"Boettcher","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omton.2026.201158_bib27","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","article-title":"Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion","volume":"36","author":"Olson","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201158_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add7900","article-title":"Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity","volume":"15","author":"Vander Mause","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201158_bib29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/cells9030729","article-title":"Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature","volume":"9","author":"Fonseca","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.omton.2026.201158_bib30","first-page":"114","article-title":"Characterization of normal human CD3+ CD5- and gamma delta T cell receptor positive T lymphocytes","volume":"80","author":"Spour","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omton.2026.201158_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adn6509","article-title":"CD5 deletion enhances the antitumor activity of adoptive T cell therapies","volume":"9","author":"Patel","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omton.2026.201158_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-136860","article-title":"CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells","volume":"136","author":"Chun","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201158_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00262-022-03260-y","article-title":"CAR \u03b3\u03b4 T cells for cancer immunotherapy. Is the field more yellow than green?","volume":"72","author":"Ganapathy","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201158_bib34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omton.2026.201158_bib35","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.178.7.4650","article-title":"T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells","volume":"178","author":"Hombach","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201158_bib36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","article-title":"CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond","volume":"23","author":"Chang","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omton.2026.201158_bib37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","article-title":"PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells","volume":"30","author":"Lee","year":"2022","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:30:22Z","timestamp":1778272222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329926000342"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201158","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigen-binding affinity is a key determinant of the durable antitumor activity of CD5 CAR-T cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201158"}}